user

Health utilities in Alzheimer’s disease and implications for cost-effectiveness analysis

被引：0
|
作者：
Peter J. Neumann
机构：
[1] Harvard School of Public Health,Department of Health Policy and Management and Center for Risk Analysis
来源：
PharmacoEconomics | 2005年 / 23卷
关键词：
Memantine; Rivastigmine; Health Utility; Clinical Dementia Rate; Health Utility Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The National Institute for Health and Clinical Excellence (NICE) provisional decision against memantine and other medications for Alzheimer’s disease (AD) has generated much discussion. In its decision, NICE expressed concern about the data source used for the utility scores in the industry submission of the memantine model. NICE therefore turned to an alternative data source. However, in doing so, it made the key assumption that moderate-to-severe AD patients living in the community were independent. Furthermore, the NICE data source also had its limitations.
引用
收藏
页码：537 / 541
页数：4
相关论文
共 50 条
  • [21] Commentary on "Health economics and the value of therapy in Alzheimer's disease." Cost-effectiveness studies
    Wimo, Anders
    Norlund, Anders
    [J]. ALZHEIMERS & DEMENTIA, 2007, 3 (03) : 157 - 161
  • [22] Cost-effectiveness of PET in the diagnosis of Alzheimer disease
    McMahon, PM
    Araki, SS
    Sandberg, EA
    Neumann, PJ
    Gazelle, GS
    [J]. RADIOLOGY, 2003, 228 (02) : 515 - 522
  • [23] Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease
    Valcarcel-Nazco, Cristina
    Perestelo-Perez, Lilisbeth
    Luis Molinuevo, Jose
    Mar, Javier
    Castilla, Ivan
    Serrano-Aguilar, Pedro
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (03) : 777 - 788
  • [24] The cost-effectiveness of quetiapine for Alzheimer's disease in community dwelling patients
    Getsios, D
    Proskorovsky, I
    Caro, JJ
    O'Brien, J
    Pesa, J
    Ward, AJ
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 315 - 315
  • [25] COST-EFFECTIVENESS OF DONEPEZIL IN THE TREATMENT OF PATIENTS WITH ALZHEIMER'S DISEASE: AN UPDATE
    Chyr, L. C.
    Yapici, H. O.
    Padula, W., V
    [J]. VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [26] Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease
    Lopez-Bastida, Julio
    Hart, Warren
    Garcia-Perez, Lidia
    Linertova, Renata
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (02) : 399 - 407
  • [27] STRUCTURAL UNCERTAINTY IN COST-EFFECTIVENESS MODELS OF TREATMENT FOR ALZHEIMER'S DISEASE
    Peters, J. L.
    Hoyle, M.
    Anderson, R.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A240 - A240
  • [28] Cost-effectiveness of a gene sequencing test for Alzheimer’s disease in Ontario
    Nicolas Iragorri
    Danielle Toccalino
    Sujata Mishra
    Brian CF. Chan
    Allison A. Dilliott
    John F. Robinson
    Robert A. Hegele
    Rebecca Hancock-Howard
    [J]. Journal of Community Genetics, 2023, 14 : 135 - 147
  • [29] The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer's disease
    Nichols, Linda O.
    Chang, Cyril
    Lummus, Allan
    Burns, Robert
    Martindale-Adams, Jennifer
    Graney, Marshall J.
    Coon, David W.
    Czaja, Sara
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (03) : 413 - 420
  • [30] The Cost-Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer's Disease
    Kirbaeh, Stephanie E.
    Simpson, Kit N.
    Nietert, Paul J.
    Mintzer, Jacobo E.
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 16 (03): : A71 - A72
12345